AGRX - Agile Therapeutics: Positive Study Moves Company Closer To NDA Resubmission
On February 11th, Agile Therapeutics (AGRX) reported topline results from their comparative wear study challenging the adhesion of Twirla matched against Xulane (Figure 1). Once the news hit the wire, AGRX quickly traded up above $1.00 in the premarket but was quickly hit with selling pressure at the bell. At the moment, it appears the stock is in the hands of the short-term traders but the data from the study is what the long-term investors are really interested in. The results of this comparative study are significant because of the adhesion